LAVI — Lavipharm S.A.

LAVILavipharm S.A.

ATH · GR · Healthcare · Drug Manufacturers - Specialty & Generic · lavipharm.com

1.638EUR-0.73%Mkt Cap: 273.85M EURP/E: 54.00Last update: 2026-05-14

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. …

Industry Peers

Drug Manufacturers - Specialty & Generic

SOBI

Swedish Orphan Biovitrum AB (publ)

153.14BSEKP/E 167.7

ECILC

EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.

Turk Ilac Ve Serum Sanayi Anonim Sirketi

3.09BTRY—

ROVI

Laboratorios Farmaceuticos Rovi, S.A.

3.02BEURP/E 25.0

loading…

Indicators:|

Key Statistics

Valuation

P/E (Trailing)54.00

P/E (Forward)—

PEG—

P/B4.85

P/S4.38

EV/EBITDA23.27

EV/Revenue4.80

EPS (TTM)0.03

EPS (Forward)—

Cash Flow & Leverage

FCF Yield0.60%

FCF Margin2.63%

Operating CF4.64M EUR

CapEx (TTM)9.64M EUR

Net Debt/EBITDA2.07

Net Debt26.67M EUR

Technical

SMA 501.364 (+20.1%)

SMA 2001.038 (+57.7%)

Beta1.00

S&P 52W Chg24.23%

Avg Vol (30d)284.28K

Avg Vol (10d)188.59K

Technical Indicators

RSI (14)69.2

MACD0.0934

MACD Signal0.0870

MACD Hist.+0.0064

BB Upper1.750 EUR

BB Middle1.525 EUR

BB Lower1.301 EUR

BB Width29.42%

ATR (14)0.0661 EUR

Vol Ratio (20d)0.39x

52W Range

0.734091% of range1.724

52W High1.724 EUR

52W Low0.7340 EUR

Profitability

Gross Margin47.37%

EBITDA Margin20.64%

Profit Margin16.96%

Oper. Margin20.47%

ROE16.95%

ROA7.16%

Revenue Growth55.40%

Earnings Growth—

Balance Sheet

Debt/Equity0.64

Current Ratio1.21

Quick Ratio0.65

Book Value/Sh0.3340 EUR

Cash/Share0.0360 EUR

Dividends

Fwd Div Rate0.0200 EUR

Trail. Div Rate0.0000 EUR

Div. Yield1.23%

5Y Avg Yield2.38%

Payout Ratio68.49%

Ex-Div DateJul 17, 2025

Pay DateNov 8, 1995

Splits

Last Split1:3

Split DateAug 1, 2022

Ownership

Shares Out.169.04M

Float—

Insiders61.85%

Institutions1.38%

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Company

Market Cap273.85M EUR

Enterprise Value300.52M EUR

Revenue (TTM)62.58M EUR

Gross Profit25.08M EUR

Net Income (TTM)8.98M EUR

Revenue/Share0.3720 EUR

Fiscal Year EndDec 2025

MR QuarterDec 2025

Employees285

Last Price1.638 EUR

CountryGR

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISIN—